ArticleGenetics research2026
Evaluating the Causal Roles of Matrix Metalloproteinases in Metabolic Syndrome: A Mendelian Randomization Study Highlighting MMP12 in Blood Pressure Regulation.
Article in Genetics research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThis study aims to investigate whether matrix metalloproteinases (MMPs) are associated with the risk of metabolic syndrome (MetS) and its components.
methodsWe conducted a two-sample Mendelian randomization (MR) study by using 9 types of MMPs as exposures and MetS and its components (waist circumference, essential hypertension, fasting blood glucose [FBG], high-density lipoprotein [HDL] cholesterol, and triglycerides) as outcomes. The genome-wide association study summary data of exposure and outcome were both obtained from publicly published research. Four MR analytical methods, including inverse variance weighted, MR-Egger, weighted median, and weighted mode, were applied to analyze the causality between exposure and outcome, in which IVW was employed as the primary analytical method. MR-Egger, Cochran's Q, leave-one-out (LOO), and MR pleiotropy residual sum and outlier (MR-PRESSO) were used to assess the reliability of the results of the MR analysis.
resultsGenetically determined MMP12 showed significant negative associations to the risk of essential hypertension (OR = 0.996, 95% CI: 0.993-0.998, p = 0.001). Results that were analyzed with the MR-Egger, weighted median, and weight mode were consistent with those analyzed with IVW. Although MMP12 may have a suggestive protective effect on FBG levels (OR = 0.993, 95% CI: 0.986-1, p = 0.049), this finding may be affected by potential horizontal pleiotropy and requires further validation. No causal associations were identified between other MMPs and the risk of MetS or its components.
conclusionsThis MR analysis provides evidence of causal links between MMP12 and the risk of essential hypertension, indicating that MMP12 might inform early risk stratification for specific cardiometabolic components (e.g., essential hypertension), rather than serving as a diagnostic biomarker for the composite metabolic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.